Methotrexate in the Treatment of Metastatic and Recurrent Primary Transitional Cell Carcinoma

Publisher Website
Google Scholar
Abstract
Results in a series of 60 patients with recurrent or metastatic transitional cell carcinoma of the bladder confirm that methotrexate is active as a single agent. Overall, 42% of the patients with measurable metastases and 28% with recurrent primary tumors responded for an average of 6 mo. Response rates in both groups were influenced by the stage of the primary tumor.

This publication has 5 references indexed in Scilit: